Jun 2026 (Q2 FY26) — Aug 13, 2026
ARS Pharmaceuticals Q2 FY26 — Strategic Shift to Targeted Commercialization and Financial Discipline
Read the full callARS Pharmaceuticals (SPRY) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
ARS Pharmaceuticals earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 33.7 | +114.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -182.6 | +120.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -62.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.23 +5.22% · +$0.21
Performance −57.9% 1Y
1Y: $10.05 on 17 Oct 2025 → $4.23. High $13.06 (9 Jan 2026), low $3.93 (14 Oct 2026).
- Previous close
- $4.02
- 52-week range
- $3.93 – $13.06
- One year
- −57.74%
Overview
- Symbol
- SPRY
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
ARS Pharmaceuticals earnings calls (SPRY)
Financials
What the filings say
Net profit, year on year: −39% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 87 | 8 | 16 | 33 | 28 | 23 | 34 |
| Operating profit | -22 | 47 | -37 | -48 | -53 | -41 | -60 | -61 |
| Operating margin | −1051.6% | 54.5% | −466.3% | −302.9% | −163.7% | −147.6% | −265.2% | −182.6% |
| Net profit | -19 | 50 | -34 | -45 | -51 | -41 | -61 | -62 |
| EPS ($ per share) | -0.20 | — | -0.35 | -0.46 | -0.52 | — | -0.61 | -0.63 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -97 | -42 | -77 | -131 | -123 | -295 |
| Total liabilities | 12 | 17 | 9 | 2 | 94 | 213 |
| Fixed assets | 2 | 0 | 0 | 1 | 1 | 2 |
| Investments | — | 0 | 64 | 157 | 263 | 204 |
| Total assets | 395 | 61 | 281 | 233 | 351 | 328 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -31 | -18 | -40 | -59 | 14 | -171 |
| Cash from investing | -1 | -0 | -0 | -87 | -106 | 57 |
| Cash from financing | 409 | 53 | 191 | 7 | 72 | 105 |
| Net cash flow | — | 36 | 150 | -140 | -20 | -9 |
| Capital expenditure | -1 | -0 | -0 | -0 | -1 | -0 |
| Free cash flow | -32 | -18 | -40 | -59 | 13 | -171 |
Insider filings
10 filings between Nov 12, 2025 and Jun 12, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.95M
5 sales by 4 insiders
40% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 3
- Option exercise — converted options into shares
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Chakma Justin | — | $1.48M | Nov 12, 2025 |
| Karas Eric | — | $250.0K | Jun 12, 2026 |
| Dorsey Brian | — | $190.0K | Nov 13, 2025 |
| Fitzpatrick Alexander A | — | $33.5K | Jun 12, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Fitzpatrick Alexander A Chief Legal Officer | Sale 10b5-1 plan | 3,355 | $33.5K |
| Jun 12, 2026 | Karas Eric Chief Commercial Officer | Option exercise 10b5-1 plan | 25,000 | $37.5K |
| Jun 12, 2026 | Karas Eric Chief Commercial Officer | Sale 10b5-1 plan | 25,000 | $250.0K |
| Nov 13, 2025 | Dorsey Brian Chief Operating Officer | Option exercise | 21,828 | $14.0K |
| Nov 13, 2025 | Dorsey Brian Chief Operating Officer | Sale | 21,828 | $190.0K |
| Nov 12, 2025 | Shah Pratik Director | Gift | 100,000 | $0 |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Sale | 136,380 | $1.21M |
| Nov 12, 2025 | Shah Pratik Director | Gift | 250,000 | $0 |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Sale | 30,000 | $267.4K |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Option exercise | 30,000 | $25.2K |
| Aug 21, 2025 | Scott Kathleen D. Chief Financial Officer | Sale 10b5-1 plan | 12,500 | $187.5K |
| Aug 21, 2025 | Scott Kathleen D. Chief Financial Officer | Option exercise 10b5-1 plan | 12,500 | $18.8K |
| Aug 21, 2025 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 plan | 50,000 | $724.3K |
| Aug 20, 2025 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 37,656 | $530.6K |
| Aug 19, 2025 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 12,344 | $173.1K |
| Jul 1, 2025 | Karas Eric Chief Commercial Officer | Sale 10b5-1 plan | 15,000 | $254.9K |
| Jul 1, 2025 | Karas Eric Chief Commercial Officer | Option exercise 10b5-1 plan | 15,000 | $22.5K |
| Jun 27, 2025 | Flynn James E 10% owner | Sale | 370,075 | $6.83M |
| Jun 27, 2025 | Flynn James E 10% owner | Sale | 370,074 | $6.83M |
| Jun 18, 2025 | Karas Eric Chief Commercial Officer | Sale 10b5-1 plan | 15,000 | $240.0K |
| Jun 18, 2025 | Karas Eric Chief Commercial Officer | Option exercise 10b5-1 plan | 15,000 | $22.5K |
| May 20, 2025 | Scott Kathleen D. Chief Financial Officer | Option exercise | 50,000 | $75.0K |
| May 20, 2025 | SAUNDERS BRENT L Director | Option exercise | 120,000 | $121.2K |
| May 20, 2025 | Fitzpatrick Alexander A Chief Legal Officer | Sale | 102,969 | $1.45M |
| May 20, 2025 | Fitzpatrick Alexander A Chief Legal Officer | Option exercise | 100,000 | $558.0K |
| May 20, 2025 | SAUNDERS BRENT L Director | Sale | 120,000 | $1.71M |
| May 20, 2025 | Scott Kathleen D. Chief Financial Officer | Sale | 50,000 | $705.2K |
| Apr 7, 2025 | Shawver Laura Director | Sale 10b5-1 plan | 50,002 | $615.1K |
| Apr 7, 2025 | Shawver Laura Director | Option exercise 10b5-1 plan | 27,493 | $133.3K |
| Apr 7, 2025 | Shawver Laura Director | Option exercise 10b5-1 plan | 22,509 | $109.2K |
| Mar 20, 2025 | Karas Eric Chief Commercial Officer | Sale 10b5-1 plan | 10,000 | $140.0K |
| Mar 20, 2025 | Karas Eric Chief Commercial Officer | Option exercise 10b5-1 plan | 10,000 | $15.0K |
| Mar 6, 2025 | Shawver Laura Director | Option exercise 10b5-1 plan | 49,600 | $240.6K |
| Mar 6, 2025 | Shawver Laura Director | Sale 10b5-1 plan | 49,600 | $556.0K |
| Mar 5, 2025 | Shawver Laura Director | Sale 10b5-1 plan | 400 | $4.4K |
| Mar 5, 2025 | Shawver Laura Director | Option exercise 10b5-1 plan | 400 | $1.9K |
| Feb 3, 2025 | Shawver Laura Director | Option exercise 10b5-1 plan | 40,936 | $198.5K |
| Feb 3, 2025 | Shawver Laura Director | Option exercise 10b5-1 plan | 9,064 | $28.6K |
| Feb 3, 2025 | Shawver Laura Director | Sale 10b5-1 plan | 50,000 | $615.6K |
| Jan 6, 2025 | Shawver Laura Director | Option exercise 10b5-1 plan | 50,000 | $157.5K |
| Jan 6, 2025 | Shawver Laura Director | Sale 10b5-1 plan | 50,000 | $555.1K |
| Dec 17, 2024 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 50,000 | $583.5K |
| Dec 17, 2024 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 50,000 | $583.6K |
| Dec 17, 2024 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 plan | 50,000 | $583.5K |
| Dec 17, 2024 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 plan | 50,000 | $583.6K |
| Dec 13, 2024 | Chakma Justin Chief Business Officer | Sale | 27,272 | $329.0K |
| Dec 13, 2024 | Chakma Justin Chief Business Officer | Option exercise | 27,272 | $39.3K |
| Dec 12, 2024 | Chakma Justin Chief Business Officer | Option exercise | 117,333 | $98.6K |
| Dec 12, 2024 | Dorsey Brian Chief Operating Officer | Sale 10b5-1 plan | 25,000 | $307.4K |
| Dec 12, 2024 | Dorsey Brian Chief Operating Officer | Option exercise 10b5-1 plan | 25,000 | $16.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ARS Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow ARS Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading